Silexion Reports New Preclinical Findings For SIL-204; Latest Preclinical Studies Reveal Significant Improvements In Stability, Efficacy, And KRAS Targeting Range For Next-generation SiRNA Candidate SIL-204
Silexion Reports New Preclinical Findings For SIL-204; Latest Preclinical Studies Reveal Significant Improvements In Stability, Efficacy, And KRAS Targeting Range For Next-generation SiRNA Candidate SIL-204
Silexion報告了SIL-204的新的臨床前研究結果；最新的臨床前研究顯示下一代SiRNA候選藥物SIL-204在穩定性、功效和KRAS靶向區間方面取得了顯著的改進
These latest findings demonstrate that the latest SIL-204-microparticle formulation can inhibit the growth and induce necrosis of the human pancreatic cell line that bears the KRAS G12D mutation xenotransplanted into mice. Given that this mutation constitutes the largest segment of pancreatic cancer subtypes, it represents a significant in the development of SIL-204.
這些最新發現表明，最新的SIL-204微粒製劑可以抑制攜帶KRAS G12D突變的人類胰腺細胞系在小鼠體內異種移植後的生長，並誘導其壞死。考慮到這一突變構成了胰腺癌亞型中最大的部分，這對於SIL-204的研發具有重要意義。